menu
    • menu

    Company profile for Kite Pharma

    NEW Drugs in Dev: 16
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development.For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potent...
    Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development.For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kite PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    333 Lakeside Drive Foster City, CA 94404
    Telephone
    Telephone
    650-574-3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kitepharma.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/kite-pharma-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/KitePharma?protected_redirect=true

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025
    Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025

    07 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251207097497/en/Yescarta-Delivers-Consistent-Safety-Efficacy-and-Quality-of-Life-Benefits-Across-Broad-Range-of-RelapsedRefractory-Large-B-cell-Lymphoma-Patients-in-New-Analysis-at-ASH-2025

    BUSINESSWIRE
    07 Dec 2025
    Share Share
    Kite Next-Gen Bicistronic CAR-T Shows Ph1 Promise in Lymphoma
    Kite Next-Gen Bicistronic CAR-T Shows Ph1 Promise in Lymphoma

    06 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251206612260/en/Kites-Next-Generation-Bicistronic-CAR-T-Cell-Therapies-Show-Encouraging-Phase-1-Results-in-RelapsedRefractory-B-Cell-Lymphoma-in-New-Data-at-ASH-2025

    BUSINESSWIRE
    06 Dec 2025
    Share Share
    Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma
    Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma

    06 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251206931756/en/Arcellx-Announces-New-Positive-Data-for-Its-iMMagine-1-Study-in-Patients-with-Relapsed-andor-Refractory-Multiple-Myeloma

    BUSINESSWIRE
    06 Dec 2025
    Share Share
    Kite Puts $1.64B On Line For Pregene's In Vivo CAR-T Deal
    Kite Puts $1.64B On Line For Pregene's In Vivo CAR-T Deal

    20 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/kite-puts-16b-line-pair-chinas-pregene-another-vivo-car-t-deal

    FIERCE BIOTECH
    20 Oct 2025
    Share Share
    Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data
    Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data

    14 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/gilead-and-kite-to-transform-cancer-care-with-new-data-at-esmo-2025-18006

    INDPHARMAPOST
    14 Oct 2025
    Share Share
    Gilead's Kite Erodes $2.3B Shoreline Cell Therapy Deal
    Gilead's Kite Erodes $2.3B Shoreline Cell Therapy Deal

    03 Sep 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gileads-kite-pharma-erodes-23b-shelf-cell-therapy-deal-shoreline-biosciences

    FIERCE BIOTECH
    03 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search